{"url_path":"/sec/maze/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219430-index.html","accession_number":"0001193125-26-219430","cik":"0001842295","ticker":"MAZE","issuer_name":"Maze Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219430-index.html","primary_entity_key":"0001842295","primary_entity_name":"Maze Therapeutics, Inc."},"word_count":355,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nEXHIBIT INDEX\n\n \n\n \n\n \n\n \n\n \n\nIncorporated by Reference\n\nExhibit\nnumber\n\n \n\nDescription of document\n\n \n\nForm\n\n \n\nFile No.\n\n \n\nNumber\n\n \n\nFiling\nDate\n\n10.1\n\n \n\n[Loan and Security Agreement, dated February 4, 2026, by and between Maze Therapeutics, Inc. and Hercules Capital, Inc.](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-ex10_19.htm)\n\n \n\n10-K\n\n \n\n001-42490\n\n \n\n10.19\n\n \n\n3/25/2026\n\n31.1\n\n \n\n[Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](maze-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n31.2\n\n \n\n[Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](maze-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n32.1*\n\n \n\n[Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](maze-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n32.2*\n\n \n\n[Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](maze-ex32_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n104\n\n \n\nCover Page formatted as Inline XBRL and contained in Exhibit 101\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFiled herewith\n\n \n\n* This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n79\n\n \n\nSignatures\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n \n\nMAZE THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n \n\n/s/ Jason Coloma\n\n \n\n \n\n \n\nJason Coloma\n\n \n\n \n\n \n\nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n\nMAZE THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n \n\n/s/ Misbah Tahir\n\n \n\n \n\n \n\nMisbah Tahir\n\n \n\n \n\n \n\nChief Financial Officer\n\n(Principal Financial Officer)\n\n \n\n \n\nMAZE THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n \n\n/s/ Amy Bachrodt\n\n \n\n \n\n \n\nAmy Bachrodt\n\n \n\n \n\n \n\nSenior Vice President, Finance\n\n(Principal Accounting Officer)\n\n \n\n80"}